Phase 2 Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Doctors believe you are expected to live at least 12 weeks or more
- You have been diagnosed (confirmed by a lab test on tissue or cell samples) with an advanced, locally spread, or metastatic (spread to other parts of the body) solid tumour that cannot be surgically removed, and your tumour has specific gene changes called RAS or RAF mutations
- Your blood counts and organ function (such as liver and kidneys) are at an acceptable level
- You have recovered from side effects caused by any previous cancer treatments
- Depending on which part of the trial you may join, your specific cancer type may need to match one of the following: advanced lung cancer (non-small cell), advanced digestive system cancers (such as pancreatic, bowel, or bile duct cancers), colorectal cancer, or other advanced solid tumours — each with specific gene mutations as described above (confirm with trial site for which group applies to you)
Who may not be able to join:
- Your cancer has a specific gene change called a MEK1/2 mutation
- You have a known allergy or sensitivity to the study drug (S241656) or any medicines used alongside it in this trial
- There is a medical reason you cannot take the chemotherapy or other anti-cancer medicines used as part of this trial
- You have had major surgery within the last 4 weeks before joining, or are planning major surgery during the trial
- You are currently receiving any other anti-cancer treatment
- You are currently receiving radiation therapy
- You have an active, serious infection (bacterial, fungal, or certain viral) that requires treatment throughout your body
- You have a significant heart or blood vessel condition
- You have symptoms from pressure on your spinal cord
- You have another active cancer (separate from the one being studied) that requires treatment within the next 2 years
- You have a history of, or current risk factors for, a specific eye condition called retinal vein occlusion (a blockage in a blood vessel in the eye) (confirm with trial site)
- You are currently pregnant or breastfeeding
- You are currently taking part in and receiving treatment on another clinical trial
- You have previously been treated with experimental drugs that targeted the same gene pathways this trial is studying (KRAS/BRAF/MEK/ERK)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33 1 55 72 60 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose Escalation: Incidence of dose-limiting toxicities (DLTs); Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs); Dose Optimization/Expansion: Objective response (OR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.